Yagita H - Search Results

1

Blockade of Notch ligand δ1 promotes allograft survival by inhibiting alloreactive Th1 cells and cytotoxic T cell generation.

Riella LV, Ueno T, Batal I, De Serres SA, Bassil R, Elyaman W, Yagita H, Medina-Pestana JO, Chandraker A, Najafian N. Riella LV, et al. Among authors: yagita h. J Immunol. 2011 Nov 1;187(9):4629-38. doi: 10.4049/jimmunol.1004076. Epub 2011 Sep 26. J Immunol. 2011. PMID: 21949024 Free PMC article.

2

Anti-CD2 mAbs suppress cytotoxic lymphocyte activity by the generation of Th2 suppressor cells and receptor blockade.

Chavin KD, Qin L, Yon R, Lin J, Yagita H, Bromberg JS. Chavin KD, et al. Among authors: yagita h. J Immunol. 1994 Apr 15;152(8):3729-39. J Immunol. 1994. PMID: 7908306

3

Superantigen-like properties of an antibody bispecific for MHC class II molecules and the V beta domain of the T cell antigen receptor.

Yagi J, Nakata M, Uchiyama T, Nishikawa M, Mizushima Y, Nishioka K, Ito K, Yagita H, Okumura K, Janeway CA Jr, et al. Yagi J, et al. Among authors: yagita h. J Immunol. 1994 Apr 15;152(8):3833-41. J Immunol. 1994. PMID: 8144952

4

CD28-independent induction of experimental autoimmune encephalomyelitis.

Chitnis T, Najafian N, Abdallah KA, Dong V, Yagita H, Sayegh MH, Khoury SJ. Chitnis T, et al. Among authors: yagita h. J Clin Invest. 2001 Mar;107(5):575-83. doi: 10.1172/JCI11220. J Clin Invest. 2001. PMID: 11238558 Free PMC article.

5

Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways.

Hayakawa Y, Takeda K, Yagita H, Van Kaer L, Saiki I, Okumura K. Hayakawa Y, et al. Among authors: yagita h. J Immunol. 2001 May 15;166(10):6012-8. doi: 10.4049/jimmunol.166.10.6012. J Immunol. 2001. PMID: 11342617

6

4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.

Cannons JL, Lau P, Ghumman B, DeBenedette MA, Yagita H, Okumura K, Watts TH. Cannons JL, et al. Among authors: yagita h. J Immunol. 2001 Aug 1;167(3):1313-24. doi: 10.4049/jimmunol.167.3.1313. J Immunol. 2001. PMID: 11466348

7

Preferential blockade of CD8(+) T cell responses by administration of anti-CD137 ligand monoclonal antibody results in differential effect on development of murine acute and chronic graft-versus-host diseases.

Nozawa K, Ohata J, Sakurai J, Hashimoto H, Miyajima H, Yagita H, Okumura K, Azuma M. Nozawa K, et al. Among authors: yagita h. J Immunol. 2001 Nov 1;167(9):4981-6. doi: 10.4049/jimmunol.167.9.4981. J Immunol. 2001. PMID: 11673505

8

TRAIL/Apo-2 ligand induces primary plasma cell apoptosis.

Ursini-Siegel J, Zhang W, Altmeyer A, Hatada EN, Do RK, Yagita H, Chen-Kiang S. Ursini-Siegel J, et al. Among authors: yagita h. J Immunol. 2002 Nov 15;169(10):5505-13. doi: 10.4049/jimmunol.169.10.5505. J Immunol. 2002. PMID: 12421926

9

The role of the CD134-CD134 ligand costimulatory pathway in alloimmune responses in vivo.

Yuan X, Salama AD, Dong V, Schmitt I, Najafian N, Chandraker A, Akiba H, Yagita H, Sayegh MH. Yuan X, et al. Among authors: yagita h. J Immunol. 2003 Mar 15;170(6):2949-55. doi: 10.4049/jimmunol.170.6.2949. J Immunol. 2003. PMID: 12626546

10

NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy.

Hayakawa Y, Screpanti V, Yagita H, Grandien A, Ljunggren HG, Smyth MJ, Chambers BJ. Hayakawa Y, et al. Among authors: yagita h. J Immunol. 2004 Jan 1;172(1):123-9. doi: 10.4049/jimmunol.172.1.123. J Immunol. 2004. PMID: 14688317

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,035 results

Search Page

Filters